Deckers shares drop 20% despite strong earnings
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Procore bolsters operations with two acquisitions
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Sonos delivers earnings win, embraces new era
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
LTC Properties reports first quarter earnings
Westlake Village-based LTC Properties, a real estate investment trust that primarily invests in seniors housing and health care properties, announced operating results for the first quarter ended March 31. LTC generated revenues worth $49 million in the first quarter of 2025, down from $51.3 million in the first quarter of 2024, which the company attributed Read More →
Mission Wealth receives investment from PE firm
Mission Wealth, a Santa Barbara financial planner firm celebrating its 25th year in business, announced it received a minority investment from private equity firm Great Hill Partners. Terms of the transaction were not disclosed. Known for investing in high-growth companies, the partnership will help Mission Wealth’s client service offering and support the firm’s national expansion Read More →
FDA lifts clinical hold on Atara’s lead treatment
Thousand Oaks-based Atara Biotherapeutics received a bit of good news on May 5, after the U.S. Food and Drug Administration announced that it has lifted its hold on Atara’s active Investigational New Drug application for the Ebvallo program. Ebvallo, which is already approved in Europe and is used for transplant-related blood cancer, was placed on Read More →
Dubroff: It’s been a tough slog from First Republic to 2025
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
